ライフサイエンスコーパス: CTC

1 CTC and CPAD vaccine strategies present cost-effective s

2 CTC and CPC characterization in humans in vivo is still

3 CTC results were revealed after endoscopic visualization

4 CTC-445.2d potently neutralized SARS-CoV-2 infection of

5 CTCs (CTC-positive; >=1 CTC/7.5 mL) were detected in 6.8

6 CTCs are a minimally invasive source of clinical informa

7 CTCs are tagged with magnetic nanoparticles conjugated t

8 CTCs as a type of tumor-derived cells are secreted by th

9 CTCs were identified in 88.1% of the HCC patients over d

10 tients' samples (9.8 +/- 5.1 vs. 1.8 +/- 2.0 CTCs mL(-1)).

11 CTCs (CTC-positive; >=1 CTC/7.5 mL) were detected in 6.8% (10/147) of the high-r

12 in 18 additional patients (testing set, 112 CTC samples) and in six SCLC patient-derived CTC explant

13 +/- SEM = 21 +/- 2.957 CTCs/mL, median = 21 CTCs/mL), demonstrating the potential clinical utility o

14 lgorithm was studied prospectively on 10,240 CTCs in 367 blood samples obtained from 294 patients wit

15 identified as high-risk groups exhibited >5 CTCs/15 mL in PPB and >50 CTCs/15 mL in IPVB.

16 roups exhibited >5 CTCs/15 mL in PPB and >50 CTCs/15 mL in IPVB.

17 ydro-Seq enables successful scRNA-seq of 666 CTCs from 21 breast cancer patient samples at high throu

18 After analysis of 88 CTCs isolated from 13 patients (training set), we genera

19 In only 3 patients (3.9%), CTCs and DTCs were detected simultaneously, whereas conc

20 prostate cancer (mean +/- SEM = 21 +/- 2.957 CTCs/mL, median = 21 CTCs/mL), demonstrating the potenti

21 The hydrodynamic force experienced by a CTC was also studied for optimal experimental conditions

22 e Johns Hopkins University modified-AdnaTest CTC AR-V7 mRNA assay and the Epic Sciences CTC nuclear-s

23 m returns the remaining blood products after CTC enrichment, permitting interrogation of larger blood

24 In multivariable analysis, CTC-status remained independent (HR: 2.4, P = 0.009) whe

25 This is the first study analyzing CTC and DTC status in 1 cohort of nonmetastatic patients

26 anking (eDAR) platform for the rare cell and CTC isolation with high throughput, greater than 90% rec

27 re CTCs as they flow through the device, and CTC-depleted blood is returned back to the mouse via the

28 k model that reconciles the level of ITH and CTC-derived gene expression data outperformed the initia

29 rognostic categories: CTC-, CTC+/AR-V7-, and CTC+/AR-V7+.

30 ll RNA-sequencing in primary bone cancer and CTCs to perform weighted gene co-expression network anal

31 ood samples containing white blood cells and CTCs.

32 ssion, and clinical significance of DTCs and CTCs are controversially discussed in the literature.

33 these nanocages were magnetic in nature, and CTCs could be captured under the influence of a magnetic

34 in vivo indwelling intravascular aphaeretic CTC isolation system to continuously collect CTCs direct

35 Immunoaffinity-based CTC isolation has also been employed in microfluidic dev

36 e-based separation with immunoaffinity-based CTC isolation.

37 date the prognostic significance of baseline CTC AR-V7 on the basis of radiographic or clinical progr

38 Because CTCs are rare and heterogeneous, their biological proper

39 elies on immunoaffinity interactions between CTCs and antibodies immobilized on magnetic particles.

40 ss by while forcing the interactions between CTCs and antibodies on the filter surfaces.

41 cally controlled microfluidic valves capture CTCs as they flow through the device, and CTC-depleted b

42 venipuncture limiting the number of captured CTCs.

43 llow for on-demand retrieval of the captured CTCs/CFNCs with high cell viability and molecular integr

44 , these devices are ineffective at capturing CTC clusters, incapable of separating clusters from sing

45 Capturing CTCs from peripheral blood is extremely challenging due

46 a novel and low-cost platform for capturing CTCs, the Si nanowires/microscale pyramids (NWs/MPs) hie

47 significant capture of renal cell carcinoma CTCs (RCC-CTCs) remains elusive due to their heterogenou

48 using three separate prognostic categories: CTC-, CTC+/AR-V7-, and CTC+/AR-V7+.

49 on largely depend on circulating tumor cell (CTC) and vascular endothelial cell (EC) interactions by

50 ports suggested that circulating tumor cell (CTC) AR-V7 detection is a poor prognostic indicator for

51 Circulating tumor cell (CTC) clusters have an enhanced capacity to initiate meta

52 Circulating tumor cell (CTC) detection offers various opportunities to advance e

53 Circulating tumor cell (CTC)-based liquid biopsies provide unique opportunities

54 Circulating tumor cells (CTC) disseminating is an important cause of distant meta

55 as also observed in circulating tumor cells (CTC) during prostate cancer metastasis.

56 oodstream as single circulating tumor cells (CTC) or multicellular CTC clusters.

57 biomarker of CIN in circulating tumor cells (CTC) that are more likely to reflect the genetic diversi

58 r interactions with circulating tumor cells (CTC) within the bloodstream, and their involvement in th

59 sis can be aided by circulating tumor cells (CTC), which also show potential to predict early relapse

60 mor DNA (ctDNA) and circulating tumor cells (CTC).

61 45 K and H1047R) in circulating tumor cells (CTCs) and cell free DNA (cfDNA).

62 tential biomarkers, circulating tumor cells (CTCs) and cell-free DNA (cfDNA), with regard to pancreat

63 tion extracted from circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), offers the poss

64 Circulating tumor cells (CTCs) and plasma levels of Epstein-Barr virus (EBV) DNA

65 Circulating tumor cells (CTCs) are an important biomarker for cancer prognosis an

66 Circulating tumor cells (CTCs) are of great interest in cancer research, but meth

67 Circulating tumor cells (CTCs) are shed into the bloodstream from primary tumors,

68 lecular analysis of circulating tumor cells (CTCs) at single-cell resolution offers great promise for

69 aches in retrieving circulating tumor cells (CTCs) at single-cell resolution, we further identified s

70 Detection of circulating tumor cells (CTCs) at the time of surgery may represent a tool to ide

71 rare cells such as circulating tumor cells (CTCs) can be generally classified into two categories: t

72 rare, heterogeneous circulating tumor cells (CTCs) can provide insight into metastasis and guide deve

73 Circulating tumor cells (CTCs) contain metastatic precursors that can initiate ne

74 Circulating tumor cells (CTCs) derived from a primary tumor can be detected in th

75 rognostic impact of circulating tumor cells (CTCs) for patients with presumed resectable pancreatic a

76 Isolation of circulating tumor cells (CTCs) from blood samples has important prognostic and th

77 sitive detection of circulating tumor cells (CTCs) from patients' peripheral blood facilitates on-dem

78 ion and analysis of circulating tumor cells (CTCs) from the blood of patients at risk of metastatic c

79 ary tumor cells and circulating tumor cells (CTCs) from the same patient.

80 ently, detection of circulating tumor cells (CTCs) has been considered as an appealing prognostic and

81 Circulating tumor cells (CTCs) have become an established biomarker for prognosis

82 For example, circulating tumor cells (CTCs) have been demonstrated as useful biomarkers for "l

83 Circulating tumor cells (CTCs) have the potential of becoming the gold standard m

84 or cells (DTCs) and circulating tumor cells (CTCs) in 1 cohort of patients with esophageal cancer (EC

85 Circulating tumor cells (CTCs) in blood can provide valuable information when det

86 es (NPs) to capture circulating tumor cells (CTCs) in blood for head and neck cancer (HNC) patients.

87 cterization of rare circulating tumor cells (CTCs) in patients' blood is important for the diagnosis

88 of neutrophils with circulating tumor cells (CTCs) in the blood of patients with breast cancer can pr

89 ic lung nodules and circulating tumor cells (CTCs) in two mouse models of mammary cancer: genetically

90 ion and analysis of circulating tumor cells (CTCs) may enable a broad range of cancer-related applica

91 Circulating tumor cells (CTCs) play a fundamental role in cancer progression.

92 The analysis of circulating tumor cells (CTCs) provides a means to collect information about the

93 Circulating tumor cells (CTCs) shed from solid tumors can serve as a minimally in

94 target the in vivo circulating tumor cells (CTCs) to suppress TNBC lung metastasis.

95 find that cultured circulating tumor cells (CTCs), derived from blood samples of women with advanced

96 targets, including circulating tumor cells (CTCs), DNA/RNA, and curcumin, and the devices were optim

97 ble in the blood as circulating tumor cells (CTCs), making them ideal targets to noninvasively profil

98 PD-L1 expression in circulating tumor cells (CTCs), may allow real-time monitoring of immune activati

99 on and detection of circulating tumor cells (CTCs).

100 latforms focused on circulating tumor cells (CTCs).

101 ence suggests that circulating tumour cells (CTCs) and bone marrow-derived disseminated tumour cells

102 Circulating tumour cells (CTCs) are rare tumour cells found in the circulatory sys

103 tastasis-competent circulating tumour cells (CTCs) experience oxidative stress in the bloodstream, bu

104 Circulating tumour cells (CTCs) survive circulatory cytotoxicity, extravasate and

105 ccines under a controlled temperature chain (CTC) protocol and the use of compact prefilled auto-disa

106 birth dose delivery strategies (cold chain, CTC) and interventions (needle and syringe, CPAD) were m

107 CTC isolation system to continuously collect CTCs directly from a peripheral vein.

108 that can be used for detecting and counting CTCs.

109 The traditional way of counting CTCs via fluorescent images requires a series of tedious

110 ns were common (Common Terminology Criteria [CTC] grade 3/4: DD 16%, DVD 18%) and likely related to a

111 three separate prognostic categories: CTC-, CTC+/AR-V7-, and CTC+/AR-V7+.

112 CTCs (CTC-positive; >=1 CTC/7.5 mL) were detected in 6.8% (10/

113 No CTCs (CTC-negative) were detected in the low-risk patients or

114 olution of cumulative technological culture (CTC) and the evolution of reasoning about abstract force

115 debate on cumulative technological culture (CTC) is dominated by social-learning discussions, at the

116 e of human cumulative technological culture (CTC), in contrast to previous accounts foregrounding soc

117 he key for cumulative technological culture (CTC), Osiurak and Reynaud argue that chimpanzees can imi

118 product of cumulative technological culture (CTC).

119 sential to cumulative technological culture (CTC).

120 to examine cumulative technological culture (CTC).

121 I welcome the authors' approach to decouple CTC from social-learning processes without minimizing th

122 A bivalent decoy, CTC-445.2d, showed ~10-fold improvement in binding.

123 The best monovalent decoy, CTC-445.2, bound with low nanomolar affinity and high sp

124 Finally, P-AscH(-) decreased CTC-derived nucleases in subjects with stage IV PDAC in

125 tion, 71.4% of the HCC patients demonstrated CTCs positive for cancer stem cell marker, CD44, suggest

126 CTC samples) and in six SCLC patient-derived CTC explant tumors.

127 polymorphisms within human xenograft-derived CTCs in mouse models.

128 sing epithelial markers to accurately detect CTCs and BM-DTCs is associated with difficulties, and pr

129 which can simultaneously isolate and detect CTCs, has great application potential in the early monit

130 The aptasensor could detect CTCs in the range of 2 to 2 x 10(6) cells mL(-1) with a

131 The nanoparticle-based approach detected CTCs from 86% of patients at baseline, compared to CellS

132 , compared to CellSearch which only detected CTCs from 60% of patients.

133 concordant results (DTC/CTC negative and DTC/CTC positive) were found in 54 patients (71.1%).

134 ultaneously, whereas concordant results (DTC/CTC negative and DTC/CTC positive) were found in 54 pati

135 Our results show effective CTC capture from HCC patients, presenting a new method f

136 Several nanostructured substrate-enabled CTC/CFNC assays are observed maturing from enumeration a

137 The CellSearch system was used to enumerate CTCs.

138 e-specific marker will be expressed on every CTC or BM-DTC throughout disease progression (giving hig

139 discussed and a decade of research examining CTCs in pancreatic cancer is summarized, including both

140 Finally, CTCs were detected in 8 out of 8 samples from patients d

141 6 to 8.1], respectively) after adjusting for CTC number and clinical prognostic factors.

142 In high-risk patients, median CSS for CTC-positive versus CTC-negative was 8.1 versus 20.0 mon

143 passes, and an array of lateral filters for CTC isolation.

144 Current methods for CTC isolation and identification are either performed on

145 which $516.5 million (75%) was required for CTC and CPAD interventions.

146 erve as an accurate and easy-to-use tool for CTC analysis.

147 Fifteen of 76 patients (19.7%) harbored CTCs, whereas in 13 of 76 patients (17.1%), DTCs could b

148 imitate mechanical actions, but do not have CTC.

149 wider electrochemical window and 70% higher CTC (charge transfer capacity) than Pt microelectrodes o

150 research tool to help reveal details of how CTCs evolve over time, allowing studies to credential ch

151 However, CTC isolation is difficult due to low CTC abundance and

152 ative selection module of PIC&RUN identifies CTCs based on a live cell dye and the absence of immune

153 itive selection module of PIC&RUN identifies CTCs based on detection of cancer surface markers and ex

154 e of detection methods available to identify CTCs.

155 and simpler way for counting and identifying CTCs.

156 mpact and cost-effectiveness of implementing CTC and CPAD interventions in the six Global Burden of D

157 nificant association between the decrease in CTC number with ALK-CNG on crizotinib and a longer PFS (

158 C mice and led to an over 2-fold increase in CTC attachment to ECs or Balb/C mouse lungs, respectivel

159 Our result shows substantial increase in CTC capture, compared with serial blood draws.

160 able biomarker of chromosomal instability in CTC is associated with poor outcomes when detected in me

161 The study identifies molecular players in CTC-neutrophil interactions, providing potential targets

162 intentional teaching plays a greater role in CTC evolution than acknowledged in the target article.

163 o the epigenetic regulation of 'stemness' in CTC clusters.

164 e, allowing studies to credential changes in CTCs as biomarkers of drug response and facilitating fut

165 nt computer vision-based biomarker of CIN in CTCs in a pretreatment sample strongly associated with p

166 PD-L1 expression in CTCs was assessed by immunofluorescence and qPCR and mon

167 simultaneously the expression of 14 genes in CTCs.

168 natures with distinct expression profiles in CTCs from patients with differing metastatic potential.

169 vivo genome-wide CRISPR activation screen in CTCs from breast cancer patients to identify genes that

170 Detection of AR-V7 in CTCs by two blood-based assays is independently associat

171 e to the resistance of anoikis and increased CTCs in the blood circulation.

172 f over 6 billion nucleated cells, increasing CTC isolation capacity by two orders of magnitude (86% r

173 p between the number of LST in an individual CTC determined by direct sequencing and morphologic feat

174 h microfluidic device to efficiently isolate CTCs from peripheral blood of HCC patients.

175 ell adhesion molecule) antibodies to isolate CTCs from human blood samples.

176 /-1.2) % efficiency and were used to isolate CTCs from patients with metastatic colorectal cancer.

177 t CNC-derived nanocages efficiently isolated CTCs from patient's blood at 85% of cell capture efficie

178 RNA sequencing of freshly isolated CTCs from breast cancer patients revealed a subset with

179 platform was further validated by isolating CTCs from blood samples of patients with metastatic panc

180 adiation therapy, the proportion of PD-L1(+) CTCs increased significantly (median 0.7% vs. 24.7%, P <

181 Overall, PD-L1(+) CTCs were detected in 25 out of 38 samples (69.4%) with

182 continuously collects fluorescently labeled CTCs from a genetically engineered mouse model (GEMM) fo

183 hed in each correlated gene set; only LIN28B CTC expression was prognostic.

184 roviding a valuable tool for downstream live CTC analyses.

185 eed multiple procedures to isolate pure live CTCs.

186 ture and Retrieval of Ultra-pure single live CTCs using Negative and positive selection (PIC&RUN).

187 Although the low CTC-rate seems a limiting factor, results indicate high

188 wever, CTC isolation is difficult due to low CTC abundance and heterogeneity.

189 ultrahigh-throughput microfluidic chip, (LP)CTC-iChip, that rapidly sorts through an entire leukaphe

190 y related to a high rate of lymphocytopenia (CTC grade 3/4: DD 20%, DVD 17%).

191 ry tumors was unaffected by activating mAbs, CTCs and tumor cells in metastatic nodules exhibited inc

192 nduced GCX degradation can enable metastatic CTC arrest.

193 gh-sensitivity profiling approach to monitor CTCs in patients with metastatic castrate-resistant pros

194 Monitoring CTCs in blood samples has increased exponentially over t

195 demonstrated by detecting significantly more CTCs in patients' samples (9.8 +/- 5.1 vs. 1.8 +/- 2.0 C

196 rculating tumor cells (CTC) or multicellular CTC clusters.

197 high-confidence associations include NEGR1, CTC-467M3.3, TMEM106B, LRFN5, ESR2, and PROX2.

198 No CTCs (CTC-negative) were detected in the low-risk patien

199 onjugated on the substrate for capturing NPC CTCs in vitro.

200 volution could not have been a key driver of CTC.

201 o the adaptive and collaborative dynamics of CTC.

202 d sufficient conditions for the emergence of CTC.

203 e informative to understand the evolution of CTC if tested in other cultural species.

204 mechanisms that can maximize the fraction of CTC clusters in circulation.

205 Univariate hazard ratio (HR) of CTC-positivity was 3.4 (P < 0.001).

206 ysis further characterizes the importance of CTC-based AR-V7 mRNA detection in predicting outcomes in

207 umor metastasis accompanied with increase of CTC numbers.

208 conditions, with undifferentiated levels of CTC-recruiting E-selectin under DF vs UF conditions.

209 e underway to assess the clinical utility of CTC and ctDNA in different settings (treatment-naive vs.

210 dition, patients positive for PD-L1 (>=5% of CTCs positive for PD-L1) at baseline had shorter PFS.

211 ltiple stages, including the accumulation of CTCs from the primary tumor and the extravasation of tum

212 Thus, preoperative analysis of CTCs by this test may guide treatment decisions and warr

213 he efficient isolation and rapid analysis of CTCs from blood.

214 A 2-fold greater attachment of CTCs to human ECs was found to occur under DF conditions

215 provides unique insights into the biology of CTCs and their mechanisms influencing metastasis, recurr

216 n - transferrin (Tf) for targeted capture of CTCs.

217 dology for the molecular characterization of CTCs and its application in breast cancer.

218 Molecular characterization of CTCs provides a unique opportunity to correlated gene se

219 bel-free enumeration and characterization of CTCs.

220 challenging due to the low concentration of CTCs.

221 y, SEM observations revealed good contact of CTCs with Si NWs/MPs substrates.

222 e review recent progress in the detection of CTCs from breast cancer with a focus on electrochemical

223 present a method for label-free detection of CTCs from patient blood samples, by taking advantage of

224 Importantly, the detection of CTCs with stemness markers and CTM provides unique insig

225 tification and quantitative determination of CTCs by aptamer-based biosensors and nanobiosensors.

226 y larger than or having similar dimension of CTCs.

227 oaffinity for enhanced capture efficiency of CTCs.

228 uid biopsy' for isolation and enumeration of CTCs for early detection of metastasis in cancer.

229 The results highlight features of CTCs associated with disease progression on abiraterone

230 lly, we discuss how further investigation of CTCs and their interacting immune cell partners may poin

231 ncer is summarized, including both levels of CTCs and analyzing their molecular characteristics and h

232 Since the migration of CTCs is an early event in cancer progression, patients w

233 r rare cell detection the very low number of CTCs in standard 10-mL peripheral blood samples limits t

234 tentially be used to analyze large number of CTCs to facilitate translation of analytical information

235 approaches used to isolate small numbers of CTCs from billions of normal blood cells.

236 hanism involved in increasing the numbers of CTCs in breast cancer is unclear.

237 The origin of CTCs and the methods of detection are discussed and a de

238 D44, suggesting that the major population of CTCs could possess stemness properties to facilitate tum

239 of the physical and biological properties of CTCs limits the efficiency of various approaches used to

240 mice, limited blood volume and the rarity of CTCs in the bloodstream preclude longitudinal, in-depth

241 ing future studies to understand the role of CTCs in metastasis.

242 However, the scarcity of CTCs and the massive contamination of blood cells limit

243 herapies targeting this aggressive subset of CTCs may merit exploration as potential suppressors of m

244 r (CTL), and a C-terminal conserved peptide (CTC).

245 gh-sensitivity method to capture and profile CTCs provides more informative data concerning the pheno

246 strate the utility of our system, we profile CTCs isolated longitudinally from animals over 4 days of

247 d of patients with breast cancer can promote CTC proliferation and metastasis.

248 Using the CTC-iChip to purify CTCs from PDAC patients for RNA-seq characterization, we

249 Together, PV-CTC enumeration and genomic profiling highlight the pote

250 PV-CTCs were detected in 48% of 100 patients enrolled into

251 ellSearch-detected pulmonary venous CTCs (PV-CTCs) at surgical resection of early-stage NSCLC represe

252 79%), suggesting that early-disseminating PV-CTCs were responsible for disease relapse.

253 omic profiling highlight the potential of PV-CTCs as early predictors of NSCLC recurrence after surge

254 define the potential clinical utility of PV-CTCs in early-stage NSCLC.

255 However, the limited sensitivity of PV-CTCs in predicting relapse suggests that further studies

256 a case study, genomic profiling of single PV-CTCs collected at surgery revealed higher mutation overl

257 Overall, the results show that quantifying CTC phenotypic heterogeneity can help inform the choice

258 high accuracy on the identification of rare CTCs without the need for advanced devices or expert use

259 tly, an antibody cocktail targeting four RCC-CTC surface receptors, which included epithelial cell ad

260 nt capture of renal cell carcinoma CTCs (RCC-CTCs) remains elusive due to their heterogenous surface

261 capture platform is developed to detect RCC-CTCs through integration of dendrimer-mediated multivale

262 red capture platform effectively detects RCC-CTCs for their potential use as tumor biomarkers.

263 mal (E/M) cells are required to recapitulate CTC size distributions with large clusters of 5 to 10 ce

264 ve cell migration and robustly recapitulates CTC cluster fractions and size distributions observed ex

265 t CTC AR-V7 mRNA assay and the Epic Sciences CTC nuclear-specific AR-V7 protein assay.

266 This platform can be used to collect single CTCs in a multiwell plate for downstream analysis.

267 ient ways to isolate and analyze live single CTCs.

268 icking protocol to retrieve ultrapure single CTCs, the positive selection module is compatible for do

269 The CellSearch system allows standardized CTC-testing and has shown excellent specificity and prog

270 nt systemically-administered agent to target CTCs and reduce cancer metastasis.

271 Patients testing CTC-positive preoperatively showed a detrimental outcome

272 The CTC isolation and sorting technology presented here prov

273 The CTC positivity rate was significantly higher in patients

274 This new assay combines the CTC capture and retrieval in one integrated platform, pr

275 patients' blood sample and compared for the CTC capturing efficiency with clinically relevant Oncovi

276 Search, the only FDA-approved method for the CTC-based cancer prognosis, relies on immunoaffinity int

277 Multivariate analyses revealed that only the CTC status was an independent predictor of overall and r

278 In this early disease stage, only the CTC status was an independent, prognostic marker suitabl

279 -hazards regression analysis showed that the CTC count in PPB or IPVB was an independent risk factor

280 Using the CTC-iChip to purify CTCs from PDAC patients for RNA-seq

281 lymph nodes have to be well examined for the CTCs presence in their blood circulation.

282 hymal marker, N-cadherin, expressed on their CTCs.

283 Therefore, CTCs can be used to monitor dynamic changes of PD-L1 dur

284 In addition, these CTCs exhibited lower EpCAM expression.

285 some and protein synthesis signatures; these CTCs expressed proliferation and epithelial markers and

286 seq barcoding technique, for high-throughput CTC analysis.

287 crucial support for a cognitive approach to CTC.

288 egrounding social-reasoning skills as key to CTC.

289 low (DF) induces GCX degradation, leading to CTC homing to the endothelium, a first step in secondary

290 ophils provides a proliferative advantage to CTCs, rendering them more competent in metastasis format

291 are immobilized with antibodies specific to CTCs and thus they function as gates, allowing normal bl

292 In other cancer types, CTCs are generally rare and noninvasive molecular detect

293 , high-gradient magnetic sorting of untagged CTCs, provides a technology for noninvasive isolation of

294 op a computer vision algorithm that utilizes CTC image features to predict the presence of a high (9

295 whether CellSearch-detected pulmonary venous CTCs (PV-CTCs) at surgical resection of early-stage NSCL

296 patients, median CSS for CTC-positive versus CTC-negative was 8.1 versus 20.0 months (P < 0.0001), an

297 immune markers, allowing retrieval of viable CTCs that are suitable for ex vivo culture.

298 ytes enables isolation of potentially viable CTCs without bias for expression of specific tumor epito

299 However, current ex vivo CTC isolation technologies rely on small blood volumes f

300 intermouse heterogeneity that can occur when CTCs are collected across different mice.

301 Surprisingly, only patients with CTCs showed significant shorter overall and relapse-free

302 h brain metastases, hypoxic signaling within CTCs predicts decreased overall survival.